NOS2 and cerebral toxoplasmosis: Protection against ocular and cerebral toxoplasmosis in Saracatinib-treated mice was not the result of increased local expression of IFN-γ, TNF-α, IL-12 p40, and NOS2, mediators of resistance against ocular and cerebral toxoplasmosis [47] (Fig 6G).